CANTOS results were presented at ESC today. Here's an ESC write up, the NEJM published study, and a Medpage Today write up. At the two higher doses, the IL-1β inhibitor antibody canakinumab lowered the risk of cardiovascular disease (primary endpoint 3-point MACE) by 14-15%. The effect was almost entirely attributable to reductions in myocardial infarctions, with no significant effects on stroke or cardiovascular death.

An added benefit of Canakinumab is a decreased risk of lung cancer. Here's the Lancet paper on the cancer study. There seems to be a catch, however. Although there was no significant different in all-cause mortality, "Canakinumab was associated with a higher incidence of fatal infection than placebo -- the rate was 0.18 in the 3,344 patient placebo group versus 0.32 among the 6,717 patients who received any dose of placebo, which worked out to 23 deaths vs 78 deaths (P=0.02)." according to the Medpage Today write up.

The anacetrapib CETP inhibitor REVEAL trial data will be presented on Tuesday.

On a side note, the first of the Resverlogix posters is up on their publications page, entitled "Lowering the Neutrophil to Lymphocyte Ratio by the BET Inhibitor, Apabetalone: Potential Implications for Cardiovascular Events in High Risk Patients."